{"id":13203,"date":"2023-10-08T20:30:00","date_gmt":"2023-10-08T12:30:00","guid":{"rendered":"https:\/\/flcube.com\/?p=13203"},"modified":"2024-11-17T20:31:40","modified_gmt":"2024-11-17T12:31:40","slug":"beijing-joins-jiangxis-interferon-volume-based-procurement-initiative","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13203","title":{"rendered":"Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative"},"content":{"rendered":"\n

The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial alliance volume-based procurement (VBP) tender. Medical institutions are required to submit their demand volumes from September 27 to October 16. The tender includes a total of 15 drug varieties across 95 different specifications, shortlisted from 18 manufacturers, including Anke Bio, Tri-Prime Gene, and Changchun Institute of Biological Products.<\/p>\n\n\n\n

National Guidelines for Centralized Procurement<\/strong><\/p>\n\n\n\n

In March of this year, the National Healthcare Security Administration (NHSA) issued guidelines regarding provincial centralized procurement and pricing management. The NHSA emphasized Jiangxi’s leadership role in the interferon inter-provincial alliance VBP, with Guangdong designated to lead in the procurement of shortage and emergency rescue drugs. As of now, provinces including Shanxi, Hunan, Beijing, and Ningxia have initiated their demand filing for the interferon VBP, with a deadline set for October 16.<\/p>\n\n\n\n

Understanding Interferons and Market Dynamics<\/strong><\/p>\n\n\n\n

Interferons (IFNs) are a class of inducible glycoproteins produced by the immune system, known for their antiviral, anti-tumor, and immunomodulatory effects. Domestic interferons are categorized into short-acting and long-acting types based on their half-life. Long-acting interferons are particularly effective for chronic hepatitis B and C, while short-acting interferons offer flexible delivery options suitable for various viral diseases and some malignant tumors. In 2020, the market size for short-acting and long-acting interferons in China reached RMB 2.231 billion (approximately USD 310 million) and RMB 9.99 billion (around USD 1.38 billion), respectively.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[82],"class_list":["post-13203","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-vbp-voluem-based-procurement"],"yoast_head":"\nBeijing Joins Jiangxi's Interferon Volume-Based Procurement Initiative - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial alliance volume-based procurement (VBP) tender. Medical institutions are required to submit their demand volumes from September 27 to October 16. The tender includes a total of 15 drug varieties across 95 different specifications, shortlisted from 18 manufacturers, including Anke Bio, Tri-Prime Gene, and Changchun Institute of Biological Products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13203\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beijing Joins Jiangxi's Interferon Volume-Based Procurement Initiative\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13203\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-08T12:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-17T12:31:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13203#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13203\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative\",\"datePublished\":\"2023-10-08T12:30:00+00:00\",\"dateModified\":\"2024-11-17T12:31:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13203\"},\"wordCount\":237,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"VBP (voluem-based procurement)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13203#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13203\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13203\",\"name\":\"Beijing Joins Jiangxi's Interferon Volume-Based Procurement Initiative - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-10-08T12:30:00+00:00\",\"dateModified\":\"2024-11-17T12:31:40+00:00\",\"description\":\"The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial alliance volume-based procurement (VBP) tender. Medical institutions are required to submit their demand volumes from September 27 to October 16. The tender includes a total of 15 drug varieties across 95 different specifications, shortlisted from 18 manufacturers, including Anke Bio, Tri-Prime Gene, and Changchun Institute of Biological Products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13203#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13203\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13203#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beijing Joins Jiangxi's Interferon Volume-Based Procurement Initiative - Insight, China's Pharmaceutical Industry","description":"The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial alliance volume-based procurement (VBP) tender. Medical institutions are required to submit their demand volumes from September 27 to October 16. The tender includes a total of 15 drug varieties across 95 different specifications, shortlisted from 18 manufacturers, including Anke Bio, Tri-Prime Gene, and Changchun Institute of Biological Products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13203","og_locale":"en_US","og_type":"article","og_title":"Beijing Joins Jiangxi's Interferon Volume-Based Procurement Initiative","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13203","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-10-08T12:30:00+00:00","article_modified_time":"2024-11-17T12:31:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13203#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13203"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative","datePublished":"2023-10-08T12:30:00+00:00","dateModified":"2024-11-17T12:31:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13203"},"wordCount":237,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["VBP (voluem-based procurement)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13203#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13203","url":"https:\/\/flcube.com\/?p=13203","name":"Beijing Joins Jiangxi's Interferon Volume-Based Procurement Initiative - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-10-08T12:30:00+00:00","dateModified":"2024-11-17T12:31:40+00:00","description":"The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial alliance volume-based procurement (VBP) tender. Medical institutions are required to submit their demand volumes from September 27 to October 16. The tender includes a total of 15 drug varieties across 95 different specifications, shortlisted from 18 manufacturers, including Anke Bio, Tri-Prime Gene, and Changchun Institute of Biological Products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13203#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13203"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13203#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13203"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13203\/revisions"}],"predecessor-version":[{"id":13204,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13203\/revisions\/13204"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}